Journal of Asthma and Allergy

Journal of Asthma and Allergy is an international, peer-reviewed, open access journal issued by Dove Medical Press, the medical imprint of the Taylor & Francis Group, and it has appeared without interruption since 2008.《哮喘与变态反应杂志》是由 Dove Medical Press 出版的国际同行评审开放获取期刊，该社为 Taylor & Francis 集团旗下的医学品牌，刊物自 2008 年起未曾间断地出版。

Its remit is the clinical side of asthma and allergic disease, running from diagnosis and epidemiology through prevention and treatment, with primary immune defects named among the topics the journal takes.其范围是哮喘与过敏性疾病的临床方面，从诊断与流行病学贯穿到预防与治疗，原发性免疫缺陷也被列为该刊接收的选题之一。

Clarivate recorded a 2025 Journal Impact Factor of 3.3 and a five-year figure of 3.7, placing the title in the second quartile of the allergy category.Clarivate 给出的 2025 年影响因子为 3.3，五年影响因子为 3.7，该刊在过敏类目中位于第二四分位。

Scope

• Asthma itself sits at the centre of the journal, which takes clinical trials, cohort studies and mechanistic work bearing directly on the disease and its treatment.哮喘本身位于该刊的中心，刊物接收与该病及其治疗直接相关的临床试验，队列研究与机制研究。

• Pulmonary physiology is named in the scope, so work on lung function, airway responsiveness and exhaled biomarkers finds a place in its pages.肺生理学被明确列入范围，因此肺功能，气道反应性与呼出气标志物方面的工作在刊内有其位置。

• Counselling and patient education carry a topic heading of their own, so work on inhaler technique, adherence and the organisation of care for people with persistent symptoms has a place.咨询与患者教育单独列为一个选题，因此吸入装置的使用技巧、依从性以及持续症状人群的照护组织方面的工作在刊内都有位置。

• Primary immune defects are named as a topic in their own right, so immunological work sits beside the asthma and allergy papers rather than in a separate journal.原发性免疫缺陷被单独列为选题，因此免疫学方面的工作与哮喘、过敏论文并列刊出，而不必另投他刊。

• Pharmacological interventions are examined, among them inhaled corticosteroids, long-acting bronchodilators and the biological agents given to patients with severe disease.药物干预受到考察，其中包括吸入糖皮质激素，长效支气管舒张剂以及用于重症患者的生物制剂。

• New therapies are reported, and a trial of a monoclonal antibody may appear beside a study of a small molecule or a novel delivery device.新疗法会被报道，单克隆抗体的试验可以与一个小分子药物或新型给药装置的研究并列出现。

• Allergy is listed as a topic beside asthma, so rhinitis, food allergy and anaphylaxis fall within the remit as well.过敏与哮喘并列为一级选题，因此鼻炎、食物过敏与严重过敏反应同样在范围之内。

• Studies that rest on cell lines or animals alone are not considered, and a submission is expected to carry clinical data, with imaging and diagnostic evidence supplied for the clinical findings.仅依赖细胞系或动物的研究不在接收之列，投稿需带有临床数据，并针对临床所见提供影像与诊断证据。

• Epidemiology belongs to the remit, so a survey of prevalence in one region may be published next to a genetic association study from another.流行病学属于刊物的职责范围，某一地区患病率的调查可以与另一地区的遗传关联研究同期刊出。

• Prevention is named among the clinical aspects the journal covers, so work on allergen avoidance and early-life exposure is considered on the same footing as treatment trials.预防被列为该刊覆盖的临床方面之一，因此变应原回避与生命早期暴露方面的工作与治疗试验受到同等考虑。

• Severe asthma receives close attention, and papers on phenotype and endotype classification, together with the selection of a biological, are common.重症哮喘受到密切关注，关于表型与内型分类以及生物制剂选择方面的论文较为常见。

• Paediatric asthma carries weight here, since the disease begins in childhood for many patients, a child's management differs from an adult's, and the editor-in-chief works in paediatric pulmonology.儿童哮喘在此有其分量，因为许多患者的疾病始于童年，儿童的管理方式与成人不同，而该刊主编本人即从事儿科呼吸专业。

• Air pollution, occupational exposure and tobacco smoke are studied as triggers, and a paper may link an environmental measure to hospital attendance.空气污染，职业暴露与烟草烟雾作为诱因受到研究，论文可以把一项环境指标与就诊人次相联系。

• Studies built on publicly available data are accepted where they add significantly to the field, and the journal asks authors to replicate the finding in their own sample rather than restate a dataset.基于公开数据的研究在能显著推进领域认识时会被接收，刊物要求作者在自己样本中复现结论，而不是复述现成数据集。

• Editorials and commentaries are published beside original research and reports, and they are used to set out the state of a question for a clinical readership.社论与评论同原创研究与报告并列刊出，该刊借它们为临床读者说明某一问题的现状。

• Case series appear, and a single case report is taken where it makes a valuable and original contribution, with imaging and diagnostic evidence attached.病例系列会刊出，单例病例报告在具有原创价值时也会被接收，并须附上影像与诊断证据。

History

• The first volume appeared in 2008 under Dove Medical Press, an open access publisher set up in 2003 and then based in Auckland.第一卷于 2008 年在 Dove Medical Press 名下问世，该社 2003 年成立，当时设在奥克兰。

• The title was launched in electronic form only, and its single number, 1178-6965, serves as both the ISSN and the eISSN.该刊以纯电子形式创办，其唯一刊号 1178-6965 在 ISSN 名录中同时登记为电子版刊号。

• From the first volume the journal was deposited in PubMed and in PubMed Central, which gave its papers a stable archive and a permanent identifier.自第一卷起该刊即存入 PubMed 与 PubMed Central，其论文因此获得稳定的存档与永久标识。

• Issue numbers were never used. Each year adds one volume and articles carry an article number instead, so the sequence runs from volume 1 in 2008 to volume 19 in 2026.该刊从不使用期号，每年增加一卷，文章以文章编号标识，卷次从 2008 年的第 1 卷延续至 2026 年的第 19 卷。

• Taylor & Francis Group bought Dove Medical Press in September 2017, and the Auckland imprint has operated inside that group ever since.Taylor & Francis 集团于 2017 年 9 月收购 Dove Medical Press，奥克兰这一品牌此后一直在该集团之内运作。

• Every article is free to read on the day it appears under a Creative Commons attribution licence, and the processing charge is met by authors or their funders.每篇文章在发表当天即可免费阅读，采用知识共享署名许可，处理费由作者或其资助方承担。

• Gold open access accounts for 99.19 per cent of the output recorded for the journal, which places it among the fully open titles of its field.该刊记录的金色开放获取比例达 99.19%，这使其位于本领域完全开放的期刊之列。

• The 2022 impact factor was 3.027. It rose to 3.7 in 2023, fell back to 3.0 in 2024 and reached 3.3 in 2025.2022 年影响因子为 3.027，2023 年升至 3.7，2024 年回落至 3.0，2025 年达到 3.3。

• Clarivate counted 126 articles in the 2025 volume and 2868 citations to the journal within the assessment window, with a cited half-life of 4.1 years.Clarivate 统计 2025 年卷载文 126 篇，评估期内对该刊的引用为 2868 次，被引半衰期为 4.1 年。

• The journal is a member of the Committee on Publication Ethics, and its editors follow that body's guidance on misconduct, retraction and correction.该刊是出版伦理委员会的成员，编辑按该机构针对不端行为与撤稿更正所定的指引行事。

• Indexing covers PubMed and PubMed Central, Scopus and Embase from 2009, the Directory of Open Access Journals and OAIster, as well as the Science Citation Index Expanded.收录范围包括 PubMed 与 PubMed Central、2009 年起的 Scopus 与 Embase、开放获取期刊目录与 OAIster，以及科学引文索引扩展版。

• Dove Medical Press keeps its editorial offices in Auckland, New Zealand, and the journal's place of publication has been recorded there since the first volume.Dove Medical Press 的编辑部设在奥克兰，该刊的出版地记录自第一卷起即为这座新西兰城市。

Editors

• Amrita Dosanjh, a board-certified paediatric pulmonologist at Rady Children's Hospital in San Diego, holds the post of editor-in-chief, and Luis Garcia-Marcos of the University of Murcia is associate editor-in-chief.主编为 Amrita Dosanjh，她是圣迭戈雷迪儿童医院的儿科呼吸专科医师，西班牙穆尔西亚大学的 Luis Garcia-Marcos 任副主编。

• The board draws its members from respiratory medicine, allergy and clinical immunology, and a manuscript is sent to a reviewer who works on its subject.编委会成员来自呼吸医学，变态反应学与临床免疫学，稿件会送给研究其主题的评审人。

• Review is anonymous on the reviewer's side, and the reports reach the editor together with a recommendation on whether the paper should proceed.评审对评审人一方匿名，评审报告连同论文是否继续处理的建议一并送达编辑。

• The editor-in-chief takes the final decision, and a revised manuscript is often returned to the reviewer who first assessed it.主编作出最终决定，修改稿常回到最初审读该稿的评审人手中。

• No enquiry to the editor is needed in the ordinary case, and a manuscript enters the online system directly with its cover letter and any suggested reviewers.通常情形下无需先向编辑咨询，稿件连同投稿信与可能推荐的评审人直接进入在线系统。

• The publisher reports a mean of 48 days from submission to a first editorial decision, nine days from acceptance to publication, and an acceptance rate of 28 per cent.出版方报告从投稿到首次编辑决定平均 48 天，从录用到上线 9 天，接受率为 28%。

• An accepted paper is typeset and placed online without waiting for the volume to close, and it is then assigned to the current volume.被接受的论文不必等到该卷编定即排版上线，随后归入当年卷次。

• Before a paper reaches a reviewer it is screened for textual overlap and for ethical approval, and the record of that screening stays in the file.稿件在送达评审人之前会经过文本重复与伦理批准的核查，核查记录留在案卷之中。

• Meta-analyses pass a pre-submission check before they are submitted, the single gate the journal puts in front of the online system.荟萃分析在投稿前须通过一次预审，这是该刊设在在线投稿系统之前的唯一一道关口。

• Correspondence about a published paper is passed to its authors, and a reply may be printed beside the letter when the point is contested.对已发表论文提出异议的来信会转交作者，论点受到质疑时回信可与来信一同刊出。